Claims for Patent: 8,663,980

Summary for Patent: 8,663,980

Title:	Vectors, host cells, and methods of production and uses
Abstract:	Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody DNA and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding DNA into the vectors. The vectors incorporate enhancer and promoter sequences that can be varied to interact with transcription factors in the host cell and thereby control transcription of the antibody-encoding DNA. A kit can incorporate these vectors and plasmids.
Inventor(s):	Carton; Jill (Radnor, PA), Lu; Jin (Radnor, PA), Scallon; Bernard J. (Radnor, PA), Snyder; Linda (Radnor, PA)
Assignee:	Janssen Biotech, Inc. (Horsham, PA)
Application Number:	12/738,453
Patent Claims:	1. A mammalian expression vector comprising the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 5, or SEQ ID NO: 6. 2. The vector of claim 1 further comprising a polynucleotide sequence encoding a variable region of an antibody. 3. The vector of claim 2 wherein the polynucleotide sequence encoding a variable region encodes a heavy or light chain of an antibody. 4. The vector of claim 1, further comprising any one of the group consisting of a 5' flanking sequence, an immunoglobulin promoter region, a cloning site, an intron enhancer region, a selectable marker, and an antibiotic resistance gene. 5. The vector of claim 4 wherein expression of the selectable marker confers resistance to at least one selected from mycophenolic acid (gpt gene), hygromycin, neomycin, Zeocin.TM., kanamycin, blasticidin, and G-418. 6. The vector of claim 4 wherein the antibiotic is selected from ampicillin, chloramphenicol, and kanamycin. 7. A host cell comprising the expression vector according to claim 1. 8. The host cell of claim 7, wherein the host cell is a mammalian host cell. 9. The host cell of claim 8 wherein the host cell is a murine myeloma host cell. 10. A kit comprising the vector of claim 1. 11. A method for producing at least one antibody, comprising translating a nucleic acid in the expression vector according to claim 2, under conditions in vitro, in vivo or in situ, wherein the antibody is expressed in detectable or recoverable amounts.

Details for Patent 8,663,980

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26